Literature DB >> 21626605

Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study.

Vincent Lo Re1, Joseph K Lim, Matthew Bidwell Goetz, Janet Tate, Harini Bathulapalli, Marina B Klein, David Rimland, Maria C Rodriguez-Barradas, Adeel A Butt, Cynthia L Gibert, Sheldon T Brown, Farah Kidwai, Cynthia Brandt, Zachariah Dorey-Stein, K Rajender Reddy, Amy C Justice.   

Abstract

PURPOSE: The absence of validated methods to identify hepatic decompensation in cohort studies has prevented a full understanding of the natural history of chronic liver diseases and impact of medications on this outcome. We determined the ability of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events within the Veterans Aging Cohort Study (VACS).
METHODS: Medical records of patients with hepatic decompensation codes and/or laboratory abnormalities of liver dysfunction (total bilirubin ≥ 5.0 g/dL, albumin ≤ 2.0 g/dL, INR ≥ 1.7) recorded 1 year before through 6 months after VACS entry were reviewed to identify decompensation events (i.e., ascites, spontaneous bacterial peritonitis, variceal hemorrhage, hepatic encephalopathy, hepatocellular carcinoma) at VACS enrollment. Positive predictive values (PPVs) of diagnostic codes, laboratory abnormalities, and their combinations for confirmed outcomes were determined.
RESULTS: Among 137 patients with a hepatic decompensation code and 197 with a laboratory abnormality, the diagnosis was confirmed in 57 (PPV, 42%; 95%CI, 33%-50%) and 56 (PPV, 28%; 95%CI, 22%-35%) patients, respectively. The combination of any code plus laboratory abnormality increased PPV (64%; 95%CI, 47%-79%). One inpatient or ≥2 outpatient diagnostic codes for ascites, spontaneous bacterial peritonitis, or variceal hemorrhage had high PPV (91%; 95%CI, 77%-98%) for confirmed hepatic decompensation events.
CONCLUSION: An algorithm of 1 inpatient or ≥ 2 outpatient codes for ascites, peritonitis, or variceal hemorrhage has sufficiently high PPV for hepatic decompensation to enable its use for epidemiologic research in VACS. This algorithm may be applicable to other cohorts.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21626605      PMCID: PMC3131229          DOI: 10.1002/pds.2148

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  35 in total

1.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

Authors:  J Bruix; M Sherman; J M Llovet; M Beaugrand; R Lencioni; A K Burroughs; E Christensen; L Pagliaro; M Colombo; J Rodés
Journal:  J Hepatol       Date:  2001-09       Impact factor: 25.083

2.  Management of adult patients with ascites due to cirrhosis: an update.

Authors:  Bruce A Runyon
Journal:  Hepatology       Date:  2009-06       Impact factor: 17.425

3.  Testing, referral, and treatment patterns for hepatitis C virus coinfection in a cohort of veterans with human immunodeficiency virus infection.

Authors:  Shawn L Fultz; Amy C Justice; Adeel A Butt; Linda Rabeneck; Sharon Weissman; Maria Rodriguez-Barradas
Journal:  Clin Infect Dis       Date:  2003-04-01       Impact factor: 9.079

4.  Three questions can detect hazardous drinkers.

Authors:  A J Gordon; S A Maisto; M McNeil; K L Kraemer; R L Conigliaro; M E Kelley; J Conigliaro
Journal:  J Fam Pract       Date:  2001-04       Impact factor: 0.493

5.  Incidence and consistency of antiretroviral use among HIV-infected medicaid beneficiaries with schizophrenia.

Authors:  J Walkup; U Sambamoorthi; S Crystal
Journal:  J Clin Psychiatry       Date:  2001-03       Impact factor: 4.384

6.  The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study.

Authors:  V Di Martino; P Rufat; N Boyer; P Renard; F Degos; M Martinot-Peignoux; S Matheron; V Le Moing; F Vachon; C Degott; D Valla; P Marcellin
Journal:  Hepatology       Date:  2001-12       Impact factor: 17.425

7.  A prospective multicenter study of hepatocellular carcinoma in italian hemophiliacs with chronic hepatitis C. The Study Group of the Association of Italian Hemophilia Centers.

Authors:  F Tradati; M Colombo; P M Mannucci; M G Rumi; C De Fazio; G Gamba; N Ciavarella; A Rocino; M Morfini; A Scaraggi; E Taioli
Journal:  Blood       Date:  1998-02-15       Impact factor: 22.113

8.  Hepatitis C is more severe in drug users with human immunodeficiency virus infection.

Authors:  R Romeo; M G Rumi; M F Donato; M A Cargnel; P Viganò; M Mondelli; B Cesana; M Colombo
Journal:  J Viral Hepat       Date:  2000-07       Impact factor: 3.728

9.  Sensitivity of an AIDS case-finding algorithm: who are we missing?

Authors:  James T Walkup; Wenhui Wei; Usha Sambamoorthi; Stephen Crystal
Journal:  Med Care       Date:  2004-08       Impact factor: 2.983

10.  Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults.

Authors:  Mark S Sulkowski; Shruti H Mehta; Michael S Torbenson; Yvonne Higgins; Sherilyn C Brinkley; Ruben Montes de Oca; Richard D Moore; Nezam H Afdhal; David L Thomas
Journal:  AIDS       Date:  2007-10-18       Impact factor: 4.177

View more
  77 in total

1.  Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation.

Authors:  David Goldberg; Ivo C Ditah; Kia Saeian; Mona Lalehzari; Andrew Aronsohn; Emmanuel C Gorospe; Michael Charlton
Journal:  Gastroenterology       Date:  2017-01-11       Impact factor: 22.682

2.  Guideline-concordant management of opioid therapy among human immunodeficiency virus (HIV)-infected and uninfected veterans.

Authors:  Julie R Gaither; Joseph L Goulet; William C Becker; Stephen Crystal; E Jennifer Edelman; Kirsha Gordon; Robert D Kerns; David Rimland; Melissa Skanderson; Daniel F Weisberg; Amy C Justice; David A Fiellin
Journal:  J Pain       Date:  2014-08-23       Impact factor: 5.820

3.  Risk of hip fracture associated with hepatitis C virus infection and hepatitis C/human immunodeficiency virus coinfection.

Authors:  Vincent Lo Re; Jessica Volk; Craig W Newcomb; Yu-Xiao Yang; Cristin P Freeman; Sean Hennessy; Jay R Kostman; Pablo Tebas; Mary B Leonard; A Russell Localio
Journal:  Hepatology       Date:  2012-10-14       Impact factor: 17.425

4.  Relationship between alcohol use categories and noninvasive markers of advanced hepatic fibrosis in HIV-infected, chronic hepatitis C virus-infected, and uninfected patients.

Authors:  Joseph K Lim; Janet P Tate; Shawn L Fultz; Joseph L Goulet; Joseph Conigliaro; Kendall J Bryant; Adam J Gordon; Cynthia Gibert; David Rimland; Matthew Bidwell Goetz; Marina B Klein; David A Fiellin; Amy C Justice; Vincent Lo Re
Journal:  Clin Infect Dis       Date:  2014-02-25       Impact factor: 9.079

5.  Decreasing mortality among patients hospitalized with cirrhosis in the United States from 2002 through 2010.

Authors:  Monica L Schmidt; A Sidney Barritt; Eric S Orman; Paul H Hayashi
Journal:  Gastroenterology       Date:  2015-01-23       Impact factor: 22.682

6.  Outcomes after hepatic encephalopathy in population-based cohorts of patients with cirrhosis.

Authors:  Elliot B Tapper; Devin Aberasturi; Zhe Zhao; Chia-Yang Hsu; Neehar D Parikh
Journal:  Aliment Pharmacol Ther       Date:  2020-05-03       Impact factor: 8.171

7.  Statins Are Associated With a Decreased Risk of Decompensation and Death in Veterans With Hepatitis C-Related Compensated Cirrhosis.

Authors:  Arpan Mohanty; Janet P Tate; Guadalupe Garcia-Tsao
Journal:  Gastroenterology       Date:  2015-10-17       Impact factor: 22.682

8.  Risk of liver decompensation with cumulative use of mitochondrial toxic nucleoside analogues in HIV/hepatitis C virus coinfection.

Authors:  Vincent Lo Re; Bret Zeldow; Michael J Kallan; Janet P Tate; Dena M Carbonari; Sean Hennessy; Jay R Kostman; Joseph K Lim; Matthew Bidwell Goetz; Robert Gross; Amy C Justice; Jason A Roy
Journal:  Pharmacoepidemiol Drug Saf       Date:  2017-07-19       Impact factor: 2.890

9.  Antiretroviral therapy reduces the rate of hepatic decompensation among HIV- and hepatitis C virus-coinfected veterans.

Authors:  Jeffrey P Anderson; Eric J Tchetgen Tchetgen; Vincent Lo Re; Janet P Tate; Paige L Williams; George R Seage; C Robert Horsburgh; Joseph K Lim; Matthew Bidwell Goetz; David Rimland; Maria C Rodriguez-Barradas; Adeel A Butt; Marina B Klein; Amy C Justice
Journal:  Clin Infect Dis       Date:  2013-11-27       Impact factor: 9.079

10.  Liver fibrosis progression in hepatitis C virus infection after seroconversion.

Authors:  Adeel A Butt; Peng Yan; Vincent Lo Re; David Rimland; Matthew B Goetz; David Leaf; Matthew S Freiberg; Marina B Klein; Amy C Justice; Kenneth E Sherman
Journal:  JAMA Intern Med       Date:  2015-02       Impact factor: 21.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.